<aside> 🚀 Discover the supporters backing our journey. Meet the VCs who believe in our vision and support our mission.
</aside>
We have raised nearly €26 million in funding from leading investors including HV Capital, Bertelsmann Healthcare Investments, Speedinvest, Cherry Ventures, and SquareOne (pre. Paua Ventures), as well as public support from FFG Austria.
Additionally, we are backed by 20+ business angels with deep expertise in MedTech, B2B SaaS, and regulatory domains. This investment fuels our mission to scale and deliver transformative solutions.
<aside> đź’¬ Felix KlĂĽhr General Partner
“Flinn combines exceptional commercial traction with best-in-class customer feedback and a compelling product vision that immediately resonates with technology investors. Above all, it is the team’s ability to move with speed and conviction, while remaining deeply committed to the medtech customers they serve and the global impact of their work, that sets them apart. We are thrilled to lead the company into its next chapter.”
</aside>
<aside> đź’¬ Tim Schneider Partner
“In Flinn, several factors came together that made us particularly excited at BHI. Bastian brings hands-on experience in MedTech, while Markus and Hasib have demonstrated their ability to build regulated products at impressive speed. We invested in Flinn because we are convinced that MedTech teams deserve a true user-first system of action, and Flinn is uniquely positioned to build it. There is a clear whitespace in the U.S. market, and we are eager to partner closely with the team to help them break through and scale in the U.S.”
</aside>
<aside> đź’¬ Filip Dames Founding Partner
"We invested in Flinn because we believe the company's innovative approach is uniquely positioned to capitalize on the evolving MedTech landscape. As regulations become more restrictive, Flinn's differentiated product offering is poised to make its mark in an underserved market. At Cherry, we are thrilled to collaborate with a team that combines deep industry expertise with cutting-edge technology, making Flinn the ideal disruptor in this new era of MedTech."
</aside>
<aside> đź’¬ Andrea Zitna Partner for Health Investments
”Regulatory, quality and compliance processes within medtech and pharma are some of the most important but also the least transparent and automated processes to manage. With the introduction of the MDR in the EU, the (already high) cost and complexity to companies to launch and manage medical products has skyrocketed. We are excited to back Flinn on their mission to change that!”
</aside>
<aside> đź’¬ Christian Buchenau Founding Partner
”We are very excited to partner with Bastian, Markus and Hasib in their quest to build a category defining company in the field of compliance tech. We know Markus since 8 years and it is for us very rewarding to partner with former SquareOne analysts when they start new companies."
</aside>
